FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 911 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Men’s skin cancer rates increase by 50% over decade June 24, 2021 Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows September 12, 2018 “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... November 25, 2020 India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration February 7, 2024 Load more HOT NEWS ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... Cancer Rehabilitation Starts at Diagnosis: Part II EMA Adopts a New Pharmaceutical Form of Selumetinib 120 years of discovery: 10 ways we’ve changed the story for...
